With three FDA-approved biologics for hidradenitis suppurativa, Jennifer Hsiao, M.D., said patient preference and access often decide which comes first.
|Slideshows|February 16, 2021
- MHE February 2021
- Volume 31
- Issue 2
Challenges Ahead in 2021
Author(s)MHE Staff
COVID-19 is the biggest one, but other twists and turns await.
Advertisement
We conducted our Challenges Ahead reader survey in January and had 101 respondents. Their answers provide understanding and insight into the thinking of healthcare executives about what lies ahead for them, their organizations and the country in 2021. Many thanks to everyone who participated!
Articles in this issue
over 5 years ago
Does the U.S. Have a Shortage of Physicians?over 5 years ago
Risky Business: Only Three of the ACA’s 23 co-ops Remainover 5 years ago
SDOH: How They Affect Cancer Rates, Care and Paymentover 5 years ago
Interoperability is Coming — at Lastover 5 years ago
Using Behavioral Economics to Influence Healthcare Decisionsover 5 years ago
Next Gen ACOs: Savers or Spenders?over 5 years ago
COVID Vaccines OK for Immunocompromisedover 5 years ago
Plot Twists for ‘Mabs’ as COVID-19 TreatmentAdvertisement
Related to this article
A structured approach grounded in implementation science and supported by a culture that values continuous improvement can enable organizations to identify barriers, align stakeholders and sustain new practices over time.
New unattended sleep testing codes take effect Jan. 1, 2027 — but a dispute over how CMS values them could shape access to the cheaper alternative to in-lab sleep studies.
A session at AAO 2026 explained how Medicare, Medicare Advantage and commercial coverage policies differ in ophthalmology, and how practices can document and code to stay compliant
Presenters at AAO 2026 examined hospital eye coverage gaps, workforce strain and how ophthalmology can gain influence within health systems.
Price transparency data on 11 glaucoma surgery codes showed payer class was most consistently tied to price, with Medicaid and self-pay rates lowest.
Experts at Fall Clinical Derm 2026 urge early JAK inhibitors over systemic steroids for atopic dermatitis and long-term vitiligo treatment, saying boxed-warning risks are overstated.
Art Papier, M.D., CEO of VisualDx, says darker skin tones have been underrepresented in dermatology resources for decades and explains how his company works backward from known diagnostic errors.
Advertisement
Advertisement
Trending on Managed Healthcare Executive
1
Ophthalmology coverage hinges on knowing the payer | AAO 2026
2
Experts urge earlier JAK inhibitor use in AD and vitiligo | Fall Clinical Derm 2026
3
A conversation about the cycle of ADHD and sleep problems in children, with Alison Pritchard, Ph.D.
4
2026 PBMI Annual National Conference
5